Skip Navigation

Cardiovascular Research 2006 69(4):899-907; doi:10.1016/j.cardiores.2005.11.016
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Goikoetxea, M. J.
Right arrow Articles by Díez, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goikoetxea, M. J.
Right arrow Articles by Díez, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease

María J. Goikoetxeaa,1, Javier Beaumonta,1, Arantxa Gonzáleza, Begoña Lópeza, Ramón Querejetab, Mariano Larmanc and Javier Díeza,d,*

aDivision of Cardiovascular Sciences, Centre for Applied Medical Research, University of Navarra, CIMA, Avda. Pío XII 55, 31008 Pamplona, Spain
bDivision of Cardiology, Donostia University Hospital, San Sebastián, Spain
cDivision of Haemodynamics, Guipuzcoa Polyclinics, San Sebastián, Spain
dDepartment of Cardiology and Cardiovascular Surgery, University Clinic, School of Medicine, University of Navarra, Pamplona, Spain

* Corresponding author. Division of Cardiovascular Sciences, Centre for Applied Medical Research, University of Navarra, CIMA, Avda. Pío XII 55, 31008 Pamplona, Spain. Tel.: +34 948194700x3000; fax: +34 948194716. Email address: jadimar{at}unav.es

Objective: To investigate whether cardiac expression of the nuclear peroxisome proliferator-activated receptor {alpha} (PPAR{alpha}) is altered in patients with hypertensive heart disease (HHD).

Methods: We studied endomyocardial septal biopsies from 24 patients with essential hypertension divided into three groups: 6 without left ventricular hypertrophy (LVH) (HT group), 10 with LVH (LVH group), and 8 with LVH and heart failure (HF) (HF group). The expression of two PPAR{alpha} isoforms (the native active and the truncated inhibitory) was analyzed by Western blot and reverse transcription polymerase chain reaction (RT–PCR), and two PPAR{alpha} target genes were evaluated by RT–PCR. Histomorphological features were evaluated in a second myocardial sample from LVH and HF groups.

Results: Whereas the expression of native PPAR{alpha} protein was lower (p<0.05) in LVH and HF groups than in the HT group, truncated PPAR{alpha} protein was overexpressed (p<0.001) in the HF group as compared with LVH and HT groups. The mRNA expression of native and truncated PPAR{alpha} was similar in the three groups of hypertensives. In addition, a progressive decrease (p for trend<0.05) in the two PPAR{alpha} target genes mRNA expression was observed among HT, LVH and HF groups. The amount of truncated PPAR{alpha} protein correlates directly with cardiomyocytes apoptosis and inversely with cardiomyocytes density in patients with HHD. In addition, the expression of truncated PPAR{alpha} protein was directly correlated with left ventricular volumes, and inversely with ejection fraction in all hypertensives.

Conclusions: These findings suggest that post-transcriptional regulation of PPAR{alpha} isoforms is altered in patients with HHD, namely in those developing HF. An excess of the truncated inhibitory isoform may be involved in hypertensive left ventricular failure and remodeling.

KEYWORDS Hypertension; Heart failure; Hypertrophy; Peroxisome proliferator-activated receptor {alpha}; Isoforms

1 The first two authors (María J. Goikoetxea and F. Javier Beaumont) contributed equally to this work.

Time for primary review 14 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
F. Djouadi, Y. Lecarpentier, J.-L. Hebert, P. Charron, J. Bastin, and C. Coirault
A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy
Cardiovasc Res, October 1, 2009; 84(1): 83 - 90.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
N. Hermida, B. Lopez, A. Gonzalez, J. Dotor, J. J. Lasarte, P. Sarobe, F. Borras-Cuesta, and J. Diez
A synthetic peptide from transforming growth factor-{beta}1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats
Cardiovasc Res, February 15, 2009; 81(3): 601 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. Beaumont, T. Arias, S. Ravassa, and J. Diez
Overexpression of human truncated peroxisome proliferator-activated receptor {alpha} induces apoptosis in HL-1 cardiomyocytes
Cardiovasc Res, August 1, 2008; 79(3): 458 - 463.
[Abstract] [Full Text] [PDF]

Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
R. Rodriguez-Calvo, L. Serrano, E. Barroso, T. Coll, X. Palomer, A. Camins, R. M. Sanchez, M. Alegret, M. Merlos, M. Pallas, et al.
Peroxisome Proliferator-Activated Receptor {alpha} Down-Regulation Is Associated With Enhanced Ceramide Levels in Age-Associated Cardiac Hypertrophy
J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2007; 62(12): 1326 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Ravassa, A. Gonzalez, B. Lopez, J. Beaumont, R. Querejeta, M. Larman, and J. Diez
Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction
Eur. Heart J., November 2, 2007; 28(22): 2785 - 2791.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B. Lopez, A. Gonzalez, J. Beaumont, R. Querejeta, M. Larman, and J. Diez
Identification of a Potential Cardiac Antifibrotic Mechanism of Torasemide in Patients With Chronic Heart Failure
J. Am. Coll. Cardiol., August 28, 2007; 50(9): 859 - 867.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.